Clofazimine: Mechanisms, Applications & Lab Use Guide

Clofazimine is a riminophenazine antimicrobial compound with potent activity against mycobacterial species, widely employed in both clinical therapy and translational research to investigate mechanisms of membrane disruption, reactive oxygen species generation, and host-directed immunomodulation.

CAS Number

2030-63-9

Molecular Formula

C₂₇H₂₂Cl₂N₄

Molecular Weight

473.40 g/mol

Appearance

Dark red to brownish-red crystalline powder

Solubility

Soluble in DMSO and chloroform; practically insoluble in water

Primary Therapeutic Use

Leprosy (Hansen's disease) and drug-resistant tuberculosis (MDR-TB)

Drug Class

Riminophenazine antibiotic

Overview and Chemical Properties

Clofazimine (CAS 2030-63-9) is a halogenated riminophenazine dye-derived compound first synthesized in the 1950s. Its molecular formula is C₂₇H₂₂Cl₂N₄ with a molecular weight of approximately 473.40 g/mol. The compound presents as a dark red to brownish-red crystalline powder and is highly lipophilic, a property that underpins both its pharmacological behavior and its preferred formulation approaches.

Due to its strong lipophilicity, clofazimine is practically insoluble in water but dissolves readily in organic solvents such as dimethyl sulfoxide (DMSO) and chloroform. For in vitro research applications, stock solutions are typically prepared in DMSO at concentrations of 10–50 mM and diluted into aqueous culture media immediately before use to minimize precipitation. Researchers should ensure that the final DMSO concentration in biological assays does not exceed 0.1–0.5% to avoid solvent-related cytotoxicity artifacts.

The characteristic deep red chromophore of clofazimine arises from its extended conjugated phenazine ring system and is relevant when interpreting colorimetric assay results, as the compound itself may contribute measurable absorbance in the visible spectrum.

Mechanism of Action

Clofazimine exerts its antimycobacterial activity through multiple, partially overlapping mechanisms that distinguish it from classical antibiotics targeting single pathways. The compound preferentially intercalates into mycobacterial DNA and has been reported to interfere with template function, thereby inhibiting mycobacterial replication. However, DNA intercalation alone does not fully account for its bactericidal potency.

A well-supported mechanism involves the generation of reactive oxygen species (ROS). Clofazimine undergoes redox cycling within mycobacterial cells: it accepts electrons from the bacterial respiratory chain (particularly at the level of NADH dehydrogenase) and then transfers them to molecular oxygen, producing hydrogen peroxide and superoxide radicals. This ROS burst inflicts oxidative damage on mycobacterial lipids, proteins, and nucleic acids, ultimately leading to cell death. Notably, the potassium transport system has also been implicated, with clofazimine disrupting K⁺ ion homeostasis across the bacterial membrane.

In addition to direct antibacterial effects, clofazimine demonstrates immunomodulatory properties in host cells. It has been shown to inhibit T-lymphocyte proliferation and modulate macrophage activity, which may contribute to its anti-inflammatory effects observed clinically in leprosy patients. These host-directed effects are of growing research interest in the context of drug-resistant tuberculosis and non-tuberculous mycobacterial infections.

Research Applications

Clofazimine serves as a valuable tool compound across several active areas of biomedical research. Its primary research applications include:

• Drug-Resistant Tuberculosis (MDR/XDR-TB): Clofazimine is a component of WHO-recommended regimens for multidrug-resistant tuberculosis. Researchers use it in in vitro minimum inhibitory concentration (MIC) assays, time-kill kinetics studies, and in vivo murine infection models to evaluate its contribution to combination regimens and to identify synergistic drug partners.
• Non-Tuberculous Mycobacteria (NTM): With the rising prevalence of NTM lung disease, clofazimine is investigated against organisms such as Mycobacterium abscessus and Mycobacterium avium complex (MAC), where standard antibiotic options are limited.
• Mechanism of Resistance Studies: Laboratory-generated clofazimine-resistant strains are used to map resistance loci, including mutations in the Rv0678 transcriptional repressor gene that upregulate the MmpL5 efflux pump in M. tuberculosis.
• Host-Directed Therapy (HDT): Researchers investigate clofazimine's immunomodulatory properties in macrophage infection models, examining its capacity to enhance phagolysosomal killing independent of direct bactericidal activity.
• Cancer Biology: Emerging evidence suggests clofazimine may induce apoptosis in certain cancer cell lines via ROS-dependent pathways, making it a candidate for repositioning studies.

When designing experiments, researchers should account for clofazimine's tendency to accumulate within lysosomes and form drug-crystal inclusions (biocrystals) in macrophages at higher concentrations, which can influence intracellular pharmacokinetics measurements.

Storage, Handling & Safety Guidelines

Storage: Clofazimine should be stored at room temperature (15–25 °C) in a tightly sealed container, protected from light and moisture. Prolonged exposure to light can cause photodegradation of the chromophore system. Under recommended storage conditions, the compound is expected to maintain integrity for the duration indicated on the product certificate of analysis (CoA). Aliquoting stock solutions into amber vials is recommended to minimize repeated freeze-thaw cycles and light exposure.

Handling: Standard laboratory personal protective equipment (PPE) should be worn when handling clofazimine, including nitrile gloves, a laboratory coat, and safety glasses. The compound's characteristic deep red pigmentation will stain skin and clothing; handle with care to avoid contact. Work in a well-ventilated area or a chemical fume hood when preparing concentrated solutions in organic solvents.

Solution Preparation: For aqueous biological media, prepare a concentrated DMSO stock (≥10 mM), vortex thoroughly to ensure complete dissolution, then dilute serially into the desired aqueous medium. Filter sterilization through a 0.2 µm PTFE membrane is recommended for cell culture applications (avoid cellulose acetate membranes, which may adsorb the lipophilic compound).

Waste Disposal: Dispose of clofazimine-containing waste in accordance with institutional chemical waste management policies and applicable local regulations. Do not pour DMSO solutions or organic solvent solutions down the drain.

Quality Specifications and Ordering Information

Aladdin Scientific's Clofazimine (SKU: C129483) is offered as a research-grade reagent with purity confirmed by HPLC analysis. The certificate of analysis (CoA), including lot-specific purity data, NMR characterization, and HPLC chromatogram, is available for download on the product page or upon request from our technical support team.

Key Specification Parameters:

• Purity: ≥98% (HPLC) — verify exact lot value on CoA
• Appearance: Dark red to brownish-red crystalline powder
• Identification: Confirmed by ¹H NMR and MS
• CAS: 2030-63-9

For bulk quantities, custom packaging, or requests for additional analytical data (residual solvents, heavy metals), please contact Aladdin Scientific's sales team. Pricing, availability, and volume discount information are accessible through the online catalog or by submitting an inquiry through the website. Researchers requiring a safety data sheet (SDS) may download it directly from the product listing page.

Frequently asked questions

What solvents are recommended for preparing clofazimine stock solutions for cell culture?

DMSO is the preferred solvent for preparing clofazimine stock solutions due to the compound's poor aqueous solubility. Prepare stocks at ≥10 mM in DMSO, then dilute into culture medium immediately before use. Ensure the final DMSO concentration in the assay well does not exceed 0.1–0.5% to avoid solvent cytotoxicity. Chloroform can be used for analytical preparations but is not suitable for biological assays.

How should clofazimine be stored to ensure long-term stability?

Store clofazimine as a solid at room temperature (15–25 °C) in a tightly sealed container away from light and moisture. For prepared DMSO stock solutions, aliquot into amber microcentrifuge tubes to minimize freeze-thaw cycles and light-induced degradation. Always consult the lot-specific certificate of analysis for confirmed expiry and storage recommendations.

Can clofazimine's red color interfere with absorbance-based assays such as MTT or resazurin viability assays?

Yes, clofazimine's deep red chromophore absorbs in the visible spectrum and can contribute background absorbance in colorimetric assays, particularly at higher compound concentrations. Researchers should include compound-only (no-cell) control wells at each concentration tested to subtract background absorbance values. Luminescence-based viability assays (e.g., CellTiter-Glo) are generally less susceptible to this interference and may be preferred for dose-response experiments with clofazimine.

What is the significance of Rv0678 mutations in clofazimine resistance research?

Rv0678 encodes a transcriptional repressor in Mycobacterium tuberculosis that normally suppresses expression of the MmpL5 efflux pump. Loss-of-function mutations in Rv0678 lead to overexpression of MmpL5, resulting in increased efflux of clofazimine and cross-resistance to bedaquiline. Monitoring Rv0678 mutation status is therefore important in clinical and laboratory resistance surveillance for MDR-TB treatment regimens containing clofazimine.

Is clofazimine suitable for use in animal infection models, and what formulation approaches are used?

Yes, clofazimine is routinely used in murine tuberculosis and NTM infection models. Common formulation approaches include suspension in 0.5% methylcellulose with 0.2% Tween 80 for oral gavage administration, or encapsulation in lipid-based vehicles to improve bioavailability given the compound's high lipophilicity. Researchers should validate the formulation's stability and homogeneity and confirm institutional animal ethics approval before proceeding with in vivo studies.

References

1. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. Clofazimine: current status and future prospects. J Antimicrob Chemother. 2012;67(2):290-298. doi:10.1093/jac/dkr444
2. Yano T, Kassovska-Bratinova S, Teh JS, et al. Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011;286(12):10276-10287. doi:10.1074/jbc.M110.200501
3. Bloemberg GV, Keller PM, Stucki D, et al. Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis. N Engl J Med. 2015;373(20):1986-1988. doi:10.1056/NEJMc1505196
4. WHO. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.